Minimal residual disease negativity does not overcome poor prognosis in high risk multiple myeloma: a single center retrospective study

ConclusionGenetic abnormalities (FISH/GEP) remain a powerful prognostic indicator for myeloma regardless of MRD status. For newly diagnosed myeloma patients treated with novel triple initial therapy and frontline ASCT, achieving MRD negative status didn’t mitigate poor prognosis outcomes of high-risk MM patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionHigh-dose chemotherapy and autologous stem cell transplant using TBC conditioning for both PCNSL and secondary CNS non-Hodgkin lymphoma appears to have encouraging long term efficacy with manageable side effects.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionT2B2F is associated with a higher incidence of acute GVHD compared with T1B2F. These results suggest that a lower dose-intensity of thiotepa and busulfan in the TBF regimen may yield better results in patients with AML in CR.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We retrospectively analyzed 48 CNS lymphoma patients who received HDC/ASCT using TBC conditioning. We found a 2-year PFS and OS rate of 80.5% and 80.1%, respectively. Toxicities included nausea/vomiting, diarrhea, mucositis, and febrile neutropenia. Treatment-related mortality was 8.3% in the first 100 days post-transplant. This data supports the use of consolidative ASCT in PCNSL and secondary CNS lymphoma patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 12 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): O.V. Lazareva, A.G. Turkina, E.Yu Chelysheva, A.A. Kulikovsky, M.A. Galayko, O.M. Senderova, V.M. Pepeliaeva, S.V. Meresiy, A.S. Luchinin, G.I. Milutina, L.V. Gavrilova, L.B. Avdeeva, E.B. Dasheeva, O.Yu Vinogradova, H.L. Julhakyan, S.M. KulikovIntroductionRussia took part in the multicenter population-based Study (Europe) and included 6.8% adult patients (pts) with newly diagnosed chronic myeloid leukemia (CML) (Hoffman V et al. 2016).ObjectiveTo analyze the mortality in the Russian cohort of patients (pts) with new...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “Wh...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
ConclusionGenetic abnormalities remain a powerful prognostic indicator for MM, regardless of MRD status. For newly diagnosed MM patients treated with novel triple-drug initial therapy and frontline autologous stem-cell transplantation, MRD-negative status did not mitigate the poor-prognosis outcomes of high-risk MM patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 4 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Efstathios Kastritis, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, Magdalini Migkou, Dimitra Gika, Despina Fotiou, Nikolaos Kanellias, Dimitrios C. Ziogas, Ioannis Ntanasis-Stathopoulos, Despoina Mparmparousi, Anastasia Gatou, Despina Katopi, Efstathios Manios, Michail Liontos, Stavroula Giannouli, Panagiotis Tsirigotis, Evangelos Terpos, Meletios A. DimopoulosAbstractPatients relapsing early after autologous stem cell transplantation (ASCT) are a particular therapeutic challenge. Among 297...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsDespite several limitations affect this analysis, especially related to the heterogeneity of the studies included, MCL is an 18F-FDG-avid lymphoma in most of the cases, with the exception of BM and GI disease. Moreover, 18F-FDG PET/CT seems to be useful in evaluating treatment response and prognosis.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 2 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Fouad Kerbage, Riwa Sakr, Valerie Lapierre, Kamelia Alexandrova, Tereza Coman, Severine Leroux, Nolwenn Lucas, Sylvain Pilorge, Eric Solary, Jean-henri Bourhis, Cristina Castilla-LlorenteAbstractAllogeneic hematopoietic cell transplantation (AHCT) represents the only curative therapy for many hematological malignancies. The graft versus leukemia effect, driven by donor T cells, plays a major role in its curative potential. This effect is sometimes very evident when patients with acute myeloid leukemia and myelodysplasi...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Myeloma patients that relapse early, within less than 12 months, after an autologous stem cell transplantation have a very poor outcome with a median post-transplant survival of just 18 months. Their outcome has not improved significantly over time. These myeloma patients relapsing early after transplant comprise an ultra-high risk group that urgently needs more effective therapies.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Cancer & Oncology | Fish | Leukemia | Lymphoma | Myeloma | Statistics | Study | Transplants